Poor
Not Aligned
Patient Risk:
Moderate
Summary
Overall alignment is poor. Several claims are not supported by the provided FDA label text, including a specific quantitative frequency for muscle weakness, mechanistic assertions about muscle-cell function, non-labeled CoQ10 supplementation, and multiple contributor claims (dehydration, hypothyroidism/anemia) plus an abrupt-discontinuation cardiovascular risk claim. The evaluation dataset provided does not cover many core label areas (dose, boxed warnings, contraindications, interactions, administration), limiting completeness.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is an HMG-CoA reductase inhibitor (statin) medication.
Supported by 11 DESCRIPTION and 12.1 Mechanism of Action.
Lipitor works by blocking cholesterol production in the liver.
Supported by 11 DESCRIPTION; 12.1 Mechanism of Action; 12.2 Pharmacodynamics.
Lipitor lowers low-density lipoprotein (LDL) cholesterol in the blood.
Supported by 12.1 Mechanism of Action (LDL-C reduction).
Lipitor may contribute to muscle weakness and fatigue in some individuals.
Supported by 5.1 Skeletal Muscle (myopathy/muscle weakness) and 6.2 Postmarketing Experience (fatigue noted; class muscle adverse effects discussed in 5.1).
Unsupported Statements
By lowering LDL cholesterol, Lipitor helps reduce the risk of heart disease and stroke.
Not directly supported in the provided label excerpts; 12.1 discusses atherosclerosis risk factors but the specific clinical-outcome phrasing (heart disease and stroke risk reduction) is not supported by the provided text.
One common side effect of Lipitor is muscle weakness and fatigue.
Muscle symptoms are discussed, but 'common' and the characterization are not supported by the provided excerpts with frequency wording sufficient to justify 'common.'
Muscle weakness is reported by up to 3.9% of patients taking Lipitor.
A quantitative 'up to 3.9%' frequency for muscle weakness is not supported by the provided label text.
Lipitor-induced muscle weakness may be related to the medication’s effect on muscle cell function.
The provided labeling excerpts discuss myopathy/rhabdomyolysis mechanisms in terms of statin class effects and risk factors, but do not support the specific 'muscle cell function' mechanism statement.
A study found that atorvastatin (Lipitor) can cause a decrease in muscle cell function, leading to muscle weakness and fatigue.
External study claims are not supported by the provided label excerpts.
Coenzyme Q10 (CoQ10) supplementation may help alleviate muscle weakness and fatigue associated with Lipitor (statin) use.
No CoQ10 supplementation recommendation is supported by the provided label excerpts; this is not stated in the label text provided.
A study found that CoQ10 supplementation improved muscle strength and reduced fatigue in patients taking statins, including Lipitor.
External study claim not supported by the provided label excerpts.
Muscle weakness and fatigue associated with Lipitor are generally mild and temporary.
The provided label excerpts do not support a general statement that these symptoms are 'generally mild and temporary.'
Dehydration can exacerbate muscle weakness and fatigue.
The provided label excerpts include risk factors for rhabdomyolysis such as electrolyte disorders, but do not support dehydration as stated.
Electrolyte imbalances (potassium, sodium, and magnesium) can contribute to muscle weakness and fatigue.
Label excerpt supports 'severe metabolic, endocrine and electrolyte disorders' as a risk factor; however, it does not specifically list potassium, sodium, and magnesium or state they 'contribute to muscle weakness and fatigue' as phrased.
Certain underlying medical conditions, such as hypothyroidism or anemia, can cause muscle weakness and fatigue.
The provided label excerpts do not support hypothyroidism or anemia as specific contributors to muscle weakness/fatigue.
Stopping Lipitor abruptly can increase the risk of cardiovascular events.
No provided label excerpt supports a claim that abrupt discontinuation increases cardiovascular event risk.
Contradictions
Important Omissions
No evaluation of key FDA-label safety requirements such as contraindications, boxed warnings (if applicable), dosing/administration instructions, drug interaction/dose-limiting guidance, monitoring recommendations beyond liver function tests, and pregnancy/lactation safety. This omission limits alignment assessment for safety-critical label content.
Importance:
High
Safety Assessment
Potential Patient Risk:
Moderate
Non-label-supported claims include CoQ10 supplementation as a potential remedy and external-study mechanistic assertions; additionally, a specific quantitative frequency (up to 3.9%) and contributor claims (dehydration, hypothyroidism/anemia) may mislead readers. The absence of review for major label safety/contraindication/interaction content prevents confirmation that safety-critical guidance aligns with the label.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple statements are not supported by the provided FDA label excerpts, including specific quantitative frequency, mechanistic assertions, and CoQ10 supplementation claims.
Suggested Improvement
Restrict claims to content explicitly present in the provided label sections (e.g., statin mechanism and general skeletal muscle warnings/risk factors) and remove/replace non-labeled external study and supplement recommendations; separately evaluate and include label-required safety elements (contraindications, boxed warnings if present, dosing/administration, monitoring, and drug interaction guidance).